Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Instem boss says firm is better positioned for profitable growth than ever before

"Following a period of planned strategic progress, Instem is now undoubtedly better positioned for profitable growth than ever before”
Scientists looking into a micrscope
Instem management says the company is on track to hit full-year expectations

The boss of Instem Plc (LON:INS), a leading provider of IT solutions to life sciences firms, has said the company is “undoubtedly better positioned for profitable growth than ever before”.

Speaking in the AIM group’s half year report, chief executive Phil Reason added: “While our target markets are generally experiencing stability or growth, our focus is moving toward annually recurring revenue and higher margins, with less reliance on perpetual software license sales.”

High quality revenues

The focus paid off in the first half of the year to June 30 as well, with recurring revenues – which are good for future earnings visibility – now accounting for 63% (H1 2016: 58%) of the total revenue, which came in at £10.3mln (H1 2016: £9.1mln).

Given the “amount of operational change during the period”, top line growth of 13% isn’t to be sniffed at.

A rise in overheads, largely brought on by acquisitions made in 2016 and continued investment into its own technology, meant adjusted profit before tax slipped to £0.1mln (H1 2016: £1mln).

That should improve the second half though, with Instem expecting to realise around £0.75mln in cost savings alone.

In the longer run, the operational review carried out this year should allow the company to save the best part of £1.5mln a year.

After last year’s acquisitions, net cash stood as of 30 June stood at £1.2mln (H1 2016: £4.8mln).

Full year earnings to be in line with expectations

“The continued investment in our outsourced services team has increased our monthly revenue generation and the full benefit of the overhead reductions implemented at the end of the first half of the year will also be realised in the second half of 2017 and beyond,” Reason said.

“Consequently, we anticipate earnings for the full year to be in line with market expectations."

Underlying trading remains strong

As for what to expect in the coming months, Instem repeated its belief that underlying trading remains strong.

The AIM firm said its Regulatory Solutions Business is seeing increasing demand and continues to grow its market share thanks to the recently mandated Standard for the Exchange of Nonclinical Data (SEND).

SEND ensures that each company presents its data in a consistent format, which is what Instem helps them to do.

Elsewhere, it has seen a major expansion of a study management contract with the US government, while it has also received confirmation of a target safety assessment opportunity in its KnowledgeScan business.

Shares were down 5.3% to 160p in early deals on Tuesday.

View full INS profile View Profile

Instem Plc Timeline

Related Articles

The glass facade of a high-rise building
June 11 2018
The analysts say the Canadian firm has a 'disruptive suite of solutions' for the real estate industry in North America
Top-level domains
October 11 2018
In its interims, management undertook a full review of historic legacy agreements that led to a final US$721,000 final restructuring payment made against one agreement and an onerous contract provision on another resulting in a one-time write down for future expected losses of US$7mln with an associated US$4.1mln reduction in intangible assets to US$81.5mln.
Virtual Reality headset
May 02 2018
The integration of the group's Apollo 11 experience into the Oculus Go launch package has seen its share price rocket up over 40%

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use